Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression

Madhukar H. Trivedi, Eric Hollander, David Nutt, Pierre Blier

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Objective: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. Data Sources: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. Study Selection: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. Data Extraction: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. Data Synthesis: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. Conclusions: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.

Original languageEnglish (US)
Pages (from-to)246-258
Number of pages13
JournalJournal of Clinical Psychiatry
Volume69
Issue number2
StatePublished - Feb 2008

Fingerprint

Major Depressive Disorder
Depression
Antidepressive Agents
Therapeutics
Tachyphylaxis
Health Resources
Information Storage and Retrieval
Individuality
MEDLINE
Suicide
Neurotransmitter Agents
Dopamine
Serotonin
Norepinephrine
Delivery of Health Care
Recurrence
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. / Trivedi, Madhukar H.; Hollander, Eric; Nutt, David; Blier, Pierre.

In: Journal of Clinical Psychiatry, Vol. 69, No. 2, 02.2008, p. 246-258.

Research output: Contribution to journalArticle

@article{61bf2a14c7f2468cb0a7e0e3ea5c9a5a,
title = "Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression",
abstract = "Objective: Recent data indicate that more than 65{\%} of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. Data Sources: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. Study Selection: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. Data Extraction: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. Data Synthesis: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including {"}downstream{"} neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. Conclusions: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.",
author = "Trivedi, {Madhukar H.} and Eric Hollander and David Nutt and Pierre Blier",
year = "2008",
month = "2",
language = "English (US)",
volume = "69",
pages = "246--258",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression

AU - Trivedi, Madhukar H.

AU - Hollander, Eric

AU - Nutt, David

AU - Blier, Pierre

PY - 2008/2

Y1 - 2008/2

N2 - Objective: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. Data Sources: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. Study Selection: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. Data Extraction: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. Data Synthesis: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. Conclusions: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.

AB - Objective: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. Data Sources: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. Study Selection: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. Data Extraction: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. Data Synthesis: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. Conclusions: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.

UR - http://www.scopus.com/inward/record.url?scp=41549144879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549144879&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 246

EP - 258

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -